Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. - Wikidata - awgldk - TriplyDB

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

http://www.wikidata.org/entity/Q34101478

about

Science Review: Vasopressin and the cardiovascular system part 2 - clinical physiology Effects of YM471, a nonpeptide AVP V(1A) and V(2) receptor antagonist, on human AVP receptor subtypes expressed in CHO cells and oxytocin receptors in human uterine smooth muscle cells Vasopressin and angiotensin receptors of the medial septal area in the control of mean arterial pressure induced by vasopressin Lixivaptan - an evidence-based review of its clinical potential in the treatment of hyponatremia.Hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy.Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study.Cardiovascular agents affect the tone of pulmonary arteries and veins in precision-cut lung slices.Present and future pharmacotherapy for heart failure.Heart failure in 10 years time: focus on pharmacological treatment.New developments in the pharmacological treatment of chronic heart failure.Drug therapy in chronic heart failure.Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure.The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, OR Vasopressin receptor antagonists in the management of acute heart failure.Acutely decompensated congestive heart failure: new therapies for an old problem.Chronic heart failure: an overview of conventional treatment versus novel approaches.Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.Vasopressin antagonists in the management of heart failure.Emerging drugs for acute and chronic heart failure: current and future developments.Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials.Conivaptan: a step forward in the treatment of hyponatremia?Hyponatraemia in clinical practice.Hyponatremia and vasopressin antagonism in congestive heart failure.Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].V2 receptor antagonism with tolvaptan in heart failure.Vasopressin-induced vasoconstriction: two concentration-dependent signaling pathways.Recent advances in the treatment of hyponatremia.Vaptans and hyponatremia in critical patients Overview of emerging pharmacologic agents for acute heart failure syndromes.Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Nutrition-focused evaluation and management of dysnatremias.Arginine vasopressin receptor signaling and functional outcomes in heart failure Role of tolvaptan in acute decompensated heart failure.Role of diuretics and ultrafiltration in congestive heart failure.Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study.Emerging diuretics for the treatment of heart failure.Conivaptan: promise of treatment in heart failure.Hyponatremia in heart failure.Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.

P2860

Q24805922-E5A3F2B8-C384-4985-92F0-1A66380EB728 Q28367906-B835B1E7-DD9F-428D-BD16-4920BC1B0B91 Q28567733-27C624DE-522E-4F2C-B85A-3AA10BAC750B Q30418165-F9BA2F31-7DBD-414C-BF95-F79AEFC487ED Q30432267-3CD78A89-C488-4420-925C-1739B2885A03 Q33712822-E768A1AA-3206-49BF-BE48-B675B6EA655F Q34117883-8AB55D0D-4E1D-4E92-A3EE-91EDB26AF018 Q34706912-4BD99A1A-2A24-4072-8D39-21139DC2F9F9 Q34817094-1A00339C-967C-49FA-A6AD-A5DB6F10CC8D Q35117060-E154B5E4-F28B-47BD-88DC-0E9F23B3419A Q35518236-99154222-B2E1-4FBA-98A6-EE094D4936B9 Q35580130-ED55EEF8-8613-419A-8214-F7163CC055DC Q35657152-51E56B29-0542-4855-93CD-B2D137665B96 Q35687674-76E5E488-5581-4E6A-8B9C-11C552868415 Q36145836-72BF33B7-63B4-40AA-BA07-53F2E9A1648A Q36266039-F42887F9-26E6-408E-A89C-2DD2DC0B3551 Q36321764-A66B1125-8B0F-4CAD-B45B-0277293D63E2 Q36351998-5EFBD01D-0D5A-4646-A952-F39BB2974147 Q36752115-40DA06D5-0659-4277-9D50-CE8DA65BAFAD Q36758585-E54D368B-CF44-4175-9716-BE4256FA7597 Q36799331-027F5940-B697-4388-8CB8-124353220F3A Q36823541-115E0F73-D2D4-4D12-AF6B-B2E5A69D963B Q36841225-3704C230-B7A0-4864-A046-E963089364D3 Q36936927-E0255037-08FA-4F30-B87B-81CEF13169C2 Q36962261-70458637-81A3-4776-B38F-8CB2BEC76BA7 Q36964715-9CFFB67A-E9A8-4500-BFCF-CDC64AACB39A Q36967352-8157A7C2-9526-4845-A2BD-8FD0470BB8BC Q36979306-30884FF6-DF0C-4338-A908-70590EADC5A2 Q37058365-CEE77649-40D6-4B8E-90EE-7A34B0704CF8 Q37086309-89973D92-0074-4EDB-84FF-DDE2BB706BCA Q37108078-0C0D9F9E-385D-41BC-93F1-25E57AD61179 Q37129218-F53A47A1-5833-40A6-BCC9-A519B25AFE32 Q37149761-BDA5880D-9402-4DD4-AC65-CF0461E533C5 Q37176415-13D5109C-9184-4762-A926-5DCF1A2E1D4E Q37277415-B17C71D0-9489-437C-9885-E50D77138670 Q37308522-6C404D0E-9ECE-4F29-9F53-8D9D3E0E7C45 Q37386310-B769F05C-4381-435E-A428-BC966675B597 Q37575489-3ECFCFED-B321-4460-9405-F074F0922CD9 Q37619950-2A350B16-75AA-473B-9297-97C3DADF410F Q37717895-41080178-7DEE-4EE4-8038-C7E6623CBBEC

P2860

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

http://www.wikidata.org/entity/Q34101478

description

2001 nî lūn-bûn

@nan

2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Acute hemodynamic effects of c ...... s with advanced heart failure.

@ast

Acute hemodynamic effects of c ...... s with advanced heart failure.

@en

Acute hemodynamic effects of c ...... s with advanced heart failure.

@nl

type

label

Acute hemodynamic effects of c ...... s with advanced heart failure.

@ast

Acute hemodynamic effects of c ...... s with advanced heart failure.

@en

Acute hemodynamic effects of c ...... s with advanced heart failure.

@nl

prefLabel

Acute hemodynamic effects of c ...... s with advanced heart failure.

@ast

Acute hemodynamic effects of c ...... s with advanced heart failure.

@en

Acute hemodynamic effects of c ...... s with advanced heart failure.

@nl

P1433

Q34101478-55E5464C-DE3F-4BC6-B2B6-27C416C08789

P1476

Q34101478-48F36D35-935A-4C57-9398-75DD1774A3DD

P2093

Q34101478-393EC5A7-9B68-479E-AF99-0DD3B4A78DF7

Q34101478-5AC15E72-F0DF-4404-A235-10F9DB4D446C

Q34101478-69DB793D-B8CE-422C-90F1-74B5A3B84D02

Q34101478-7C25F31E-9814-4EEA-A834-EAB2D23CFF58

Q34101478-826BDDC3-2DBD-43E8-A1A8-AE5FDF0E479E

Q34101478-99FAFFA4-57D0-4DDA-BFB4-7D7566BE7FDC

Q34101478-BAD06004-D59E-40EA-83C1-26F069FD9984

Q34101478-E55786E1-AF29-4596-A7CD-DF42A2D095FB

Q34101478-E6FBC85E-D7E7-4CC7-803C-FF81DC3C47A8

Q34101478-ED5607DC-423D-476A-BDD7-94F8BDCF6ED7

P304

Q34101478-C504A7B5-F25B-431B-A348-8AC7E7E46DC0

P31

Q34101478-0090C1BB-60D9-4C79-B428-1E1D3BEDA704

P356

Q34101478-DAA0C13F-0C9F-4EEF-ABF8-739337A327FB

P407

Q34101478-6E7D2D1D-72E1-40BA-A687-6A645E3BB87A

P433

Q34101478-9E7F2E88-DDB3-4024-B4CA-5E3A595E5172

P478

Q34101478-32BEB7E2-CA7E-444F-995E-0656E05531DE

P577

Q34101478-97EE88E9-27FB-4D30-AB05-D1FD12E7752A

P5875

Q34101478-CC248E4B-9345-4F48-97C5-30E8F5D30704

P698

Q34101478-BA84E8D7-5760-47E0-944A-F34A551CD9AD

P921

Q34101478-0b400f3b-9d0e-4bb6-9576-b5bb53b3f59c

Q34101478-245846FC-23AE-4BBC-B497-A5CC3178DD75

Q34101478-B81ABF1F-34F2-4E08-BDA4-6D0DDC7B5D8B

Q34101478-E740E57F-5A57-4B5A-974E-24C6D0D1571A

P356

P1433

P1476

Acute hemodynamic effects of c ...... s with advanced heart failure.

@en

P2093

Chanoine F

http://www.w3.org/2001/XMLSchema#string

Ghali JK

http://www.w3.org/2001/XMLSchema#string

Ghazzi M

http://www.w3.org/2001/XMLSchema#string

Hendrix GH

http://www.w3.org/2001/XMLSchema#string

Konstam MA

http://www.w3.org/2001/XMLSchema#string

Painchaud CA

http://www.w3.org/2001/XMLSchema#string

Pressler ML

http://www.w3.org/2001/XMLSchema#string

Selaru P

http://www.w3.org/2001/XMLSchema#string

Smith WB

http://www.w3.org/2001/XMLSchema#string

Thomas I

http://www.w3.org/2001/XMLSchema#string

P304

2417-2423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/HC4501.099313

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2001-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11648743

http://www.w3.org/2001/XMLSchema#string

P698

11705818

http://www.w3.org/2001/XMLSchema#string

P921